Ongoing Clinical Trials

A Phase 2b study for patients with moderate to severe benign prostatic hyperplasia (BPH) using PRX302, was initiated in January 2009 and top-line results are expected in Q4 2009. 

In this study up to 90 patients will receive either PRX302 (3µg/ml) or placebo at a volume equivalent to 20 percent of the total prostate volume with a minimum 1.5 mL per deposit. Each dose will be delivered in three distinct deposition points along the urethra through a single ultrasound-guided transperineal injection into each lobe of the prostate. Therapeutic activity will be assessed based on symptomatic relief, prostate shrinkage and uroflow measurements at three months following a single treatment with PRX302.

For more information about this trial, please contact:

Nina Merchant
VP, Development and Regulatory Affairs
nmerchant@protoxtherapeutics.com

What's New

June 2 2010
Protox Announces Positive Six Month Phase 2B BPH Results

June 1, 2010
Protox to Present Phase 2B BPH Data at the Annual Meeting of the American Urological Association

May 13, 2010
Protox Reports First Quarter 2010 Financial Results

April 29, 2010
Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease

 

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

 

Stock Quote

LAST TRADE:$0.39
TRADE TIME:3:53PM EST
CHANGE:$0.00 (0.00%)
PREV CLOSE: $0.39
OPEN:$0.39
BID:$0.385
ASK:$0.39